Tralokinumab Treatment In Patients With Atopic Dermatitis and Moderate-to-Severe Hand Involvement: Results From the 32-Week Phase 3b ADHAND Trial. J of Skin 2026, 10 (2), s744. https://doi.org/10.25251/ppt8ep84.